The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to deliver a significant substantial decrease in body weight and enhance metabolic function